Companies /Healthcare

Verrica Pharmaceuticals Inc

NASDAQ: VRCA Biotechnology
$5.39
▲ $0.15 (+2.86%) today
Markets closed · 4:43am ET
Today · % change

Fundamentals

Market Cap
$90.0M
Profit Margin
-102.8%
Revenue (TTM)
$30.3M
EPS (TTM)
$-1.74
52-Week Range
$3 – $10
Street Target
$13.83

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a pioneering dermatology-focused biopharmaceutical company. It specializes in developing innovative treatments for skin diseases, including common and genital warts, basal cell carcinoma, and plantar warts. Its leading product, YCANTH (VP-102), is making strides in phase III trials for common warts and has shown promise in other skin conditions. The company also explores cancer treatments with VP-315 and targets plantar warts with VP-103. Founded in 2013 and based in West Chester, Pennsylvania, Verrica Pharmaceuticals is committed to advancing dermatological care worldwide.

VRCA Coverage